The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion
Rev. Assoc. Med. Bras. (1992)
;
64(3): 230-233, Mar. 2018. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-896447
ABSTRACT
Summary Objective:
The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE).Method:
Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well.Results:
The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found.Conclusion:
Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Paclitaxel
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Bevacizumab
/
Neoplasias Pulmonares
/
Antineoplásicos Fitogênicos
Tipo de estudo:
Estudo diagnóstico
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Rev. Assoc. Med. Bras. (1992)
Ano de publicação:
2018
Tipo de documento:
Artigo
País de afiliação:
China
Instituição/País de afiliação:
7 Hospital/CN
Similares
MEDLINE
...
LILACS
LIS